IMMUNOHISTOCHEMISTRY, CD 21

The Immunohistochemistry (IHC) – CD21 test is a specialized diagnostic test used to detect CD21 protein expression in tissue samples. CD21 is a surface receptor found mainly on mature B-cells and follicular dendritic cells (FDCs), making it an important marker for evaluating lymphoid tissue structure and diagnosing certain hematologic disorders.

This test is widely used in hematopathology to assess follicular dendritic cell networks and to help diagnose lymphomas and follicular dendritic cell tumors. Detecting CD21 helps pathologists identify abnormalities in lymphoid architecture and distinguish reactive lymphoid tissue from malignant lymphoma.

The CD21 marker is especially useful in diagnosing:

• Follicular lymphoma
• Follicular dendritic cell sarcoma
• Reactive lymphoid hyperplasia
• Germinal center abnormalities
• Certain B-cell lymphomas

The CD21 test helps visualize the follicular dendritic meshwork, which is often altered in lymphoma and other lymphoid neoplasms. This provides important information for accurate tissue classification.

The CD21 IHC test is often performed alongside markers such as CD23, CD35, CD20, BCL6, CD10, and Ki-67 for detailed lymphoma analysis and comprehensive tissue evaluation.

Benefits of the Test

The CD21 test offers several important clinical benefits:

• Detects follicular dendritic cell marker expression accurately
• Helps diagnose lymphoid tissue disorders
• Supports lymphoma classification
• Assists in evaluating lymph node architecture
• Improves diagnostic precision
• Helps guide treatment planning

This test is essential for accurate lymphoid tissue diagnosis.

Why Doctors Recommend This Test

Doctors recommend the CD21 test when lymphoma or lymphoid tissue abnormalities are suspected.

It is commonly advised for:

• Suspected follicular lymphoma diagnosis
• Lymph node biopsy evaluation
• Follicular dendritic cell tumor assessment
• Lymphoid tissue classification
• Advanced hematopathology confirmation cases

The results help hematologists and pathologists establish an accurate diagnosis and treatment strategy.

Preparation Before Test

No special preparation is required from the patient. The test is performed on previously collected lymph node biopsy or tissue specimens.

Normal Reporting Time

The usual turnaround time for the CD21 IHC test is 2 to 5 working days, depending on tissue complexity and laboratory workflow.

Who Should Take This Test

This test is recommended for:

• Patients with enlarged lymph nodes
• Individuals suspected of lymphoma
• Patients requiring lymphoid tissue evaluation
• Cases needing follicular dendritic network assessment
• Oncology patients requiring accurate tissue diagnosis

The IHC CD21 test is an important diagnostic tool in hematopathology. It helps assess lymphoid tissue architecture, supports accurate lymphoma classification, and improves patient management through precise diagnosis.